

Elisabeth I Heath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7841966/publications.pdf>

Version: 2024-02-01

129
papers

7,873
citations

136950
32
h-index

54911
84
g-index

131
all docs

131
docs citations

131
times ranked

11482
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	28.9	2,660
2	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11428-11436.	7.1	839
3	Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2592-2600.	1.6	404
4	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. <i>Cell</i> , 2018, 173, 1770-1782.e14.	28.9	400
5	Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with Cancer. <i>Cancer Control</i> , 2016, 23, 327-337.	1.8	303
6	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	329.8	203
7	Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 545-557.	6.3	178
8	A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7940-7946.	7.0	168
9	EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1041-1049.	1.6	159
10	Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 1737-1743.	1.6	128
11	Phase II Evaluation of Preoperative Chemoradiation and Postoperative Adjuvant Chemotherapy for Squamous Cell and Adenocarcinoma of the Esophagus. <i>Journal of Clinical Oncology</i> , 2000, 18, 868-868.	1.6	126
12	Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 872-882.	10.7	122
13	Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1432-1443.	10.7	115
14	A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. <i>Investigational New Drugs</i> , 2008, 26, 59-65.	2.6	105
15	Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis. <i>Molecular Cancer</i> , 2016, 15, 68.	19.2	89
16	The biology and rationale of targeting nectin-4 in urothelial carcinoma. <i>Nature Reviews Urology</i> , 2021, 18, 93-103.	3.8	89
17	Clinical Potential of Matrix Metalloprotease Inhibitors in Cancer Therapy. <i>Drugs</i> , 2000, 59, 1043-1055.	10.9	85
18	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 517-526.	3.9	80

#	ARTICLE	IF	CITATIONS
19	Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. , 2017, 5, 82.		77
20	A Phase Ib/Ila Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 5338-5347.	7.0	76
21	Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1374-1380.	2.5	57
22	Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Investigational New Drugs, 2002, 20, 95-99.	2.6	53
23	A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer. Clinical Prostate Cancer, 2005, 4, 138-141.	2.1	53
24	Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 978-993.	13.2	52
25	Smartphone apps for cancer: A content analysis of the digital health marketplace. Digital Health, 2020, 6, 205520762090541.	1.8	47
26	docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Investigational New Drugs, 2016, 34, 112-118.	2.6	46
27	Percutaneous Cryoablation of Renal Tumors: Is It Time for a New Paradigm? Shift?. Journal of Vascular and Interventional Radiology, 2017, 28, 1363-1370.	0.5	46
28	Mutations in β -Catenin and APC Genes are Uncommon in Esophageal and Esophagogastric Junction Adenocarcinomas. Modern Pathology, 2000, 13, 1055-1059.	5.5	44
29	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer, 2019, 17, 275-282.e1.	1.9	42
30	A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 565-573.	2.3	40
31	Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Investigational New Drugs, 2006, 24, 135-140.	2.6	37
32	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice, 2020, 16, 811-819.	2.9	35
33	Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. Urology, 2015, 86, 1206-1211.	1.0	34
34	A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Investigational New Drugs, 2012, 30, 1566-1574.	2.6	33
35	Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin. Scientific Reports, 2018, 8, 40.	3.3	32
36	Prostate Tumor Cell-Derived IL1 β Induces an Inflammatory Phenotype in Bone Marrow Adipocytes and Reduces Sensitivity to Docetaxel via Lipolysis-Dependent Mechanisms. Molecular Cancer Research, 2019, 17, 2508-2521.	3.4	32

#	ARTICLE	IF	CITATIONS
37	Racial Disparities in the Molecular Landscape of Cancer. <i>Anticancer Research</i> , 2018, 38, 2235-2240.	1.1	32
38	Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2034633.	5.9	29
39	EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931.) <i>Tj ETQq1 1 0.784314 rgBT /Overl</i>	1.6	29
40	A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183. <i>Clinical Cancer Research</i> , 2007, 13, 3906-3912.	7.0	26
41	Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials. <i>BMC Cancer</i> , 2017, 17, 807.	2.6	26
42	Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity. <i>Cancer Research</i> , 2015, 75, 3970-3979.	0.9	25
43	Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 4072-4080.	7.0	25
44	Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1549-1559.	7.0	24
45	Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 333-346.	5.9	23
46	Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 373-380.e2.	1.9	22
47	Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type. <i>Translational Oncology</i> , 2021, 14, 101016.	3.7	22
48	Maspin expression in prostate tumor elicits host anti-tumor immunity. <i>Oncotarget</i> , 2014, 5, 11225-11236.	1.8	22
49	An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1373-1382.	4.1	20
50	Discovery of primary prostate cancer biomarkers using cross cancer learning. <i>Scientific Reports</i> , 2021, 11, 10433.	3.3	19
51	Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I. <i>Oncotarget</i> , 2016, 7, 82266-82272.	1.8	18
52	Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells. <i>Molecular Pharmacology</i> , 2016, 90, 225-237.	2.3	18
53	Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer. <i>Anticancer Research</i> , 2018, 38, 6361-6366.	1.1	18
54	Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 655-663.	5.9	18

#	ARTICLE	IF	CITATIONS
55	Lysine 53 Acetylation of Cytochrome c in Prostate Cancer: Warburg Metabolism and Evasion of Apoptosis. <i>Cells</i> , 2021, 10, 802.	4.1	17
56	Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 31.e25-31.e33.	1.6	16
57	Exploring Spatial-Temporal Changes in ¹⁸ F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. <i>Journal of Clinical Oncology</i> , 2020, 38, 3662-3671.	1.6	16
58	A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. <i>Investigational New Drugs</i> , 2011, 29, 1426-1431.	2.6	15
59	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	3.9	15
60	The Effect of Race/Ethnicity on the Accuracy of the 2001 Partin Tables for Predicting Pathologic Stage of Localized Prostate Cancer. <i>Urology</i> , 2008, 71, 151-155.	1.0	14
61	Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. <i>European Urology</i> , 2022, 81, 515-522.	1.9	14
62	Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 463-471.	1.9	12
63	Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e695-e703.	1.9	12
64	Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. <i>JCO Global Oncology</i> , 2021, 7, 495-505.	1.8	12
65	Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 703-712.	2.3	11
66	Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. <i>Oncotarget</i> , 2018, 9, 35327-35342.	1.8	11
67	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K δ/ϵ , in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2257-2269.	7.0	11
68	Sample size determination for logistic regression on a logit-normal distribution. <i>Statistical Methods in Medical Research</i> , 2017, 26, 1237-1247.	1.5	10
69	Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).. <i>Journal of Clinical Oncology</i> , 2022, 40, 88-88.	1.6	10
70	Treatment Intensification Patterns and Utilization in Patients with Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 524-532.	1.9	10
71	Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus. <i>Contemporary Clinical Trials</i> , 2009, 30, 2-7.	1.8	9
72	Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. <i>Oncologist</i> , 2019, 24, 1149-e807.	3.7	9

#	ARTICLE	IF	CITATIONS
73	eHealth Activity among African American and White Cancer Survivors: A New Application of Theory. Health Communication, 2020, 35, 350-355.	3.1	9
74	Unpacking Trial Offers and Low Accrual Rates: A Qualitative Analysis of Clinic Visits With Physicians and Patients Potentially Eligible for a Prostate Cancer Clinical Trial. JCO Oncology Practice, 2020, 16, e124-e131.	2.9	9
75	Global peak alignment for comprehensive two-dimensional gas chromatography mass spectrometry using point matching algorithms. Journal of Bioinformatics and Computational Biology, 2016, 14, 1650032.	0.8	8
76	The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II. Oncotarget, 2017, 8, 17643-17650.	1.8	8
77	Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults. Expert Opinion on Biological Therapy, 2011, 11, 1519-1524.	3.1	7
78	Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, TPS5094-TPS5094.	1.6	7
79	Detecting TRA-1â€60 in Cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent. Molecular Pharmaceutics, 2020, 17, 1139-1147.	4.6	6
80	Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients. American Journal of Translational Research (discontinued), 2016, 8, 166-76.	0.0	6
81	Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 3001-3001.	1.6	6
82	Apocrine Carcinoma of the Face in a 62-Year-Old Asian Man. Clinics and Practice, 2011, 1, 100-101.	1.4	5
83	Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 6676.	4.1	5
84	Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Research, 2019, 79, CT095-CT095.	0.9	5
85	Preliminary results of a phase 1 study of sea-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2022, 40, 559-559.	1.6	5
86	Theoretical and Practical Application of Traditional and Accelerated Titration Phase I Clinical Trial Designs: The Wayne State University Experience. Journal of Biopharmaceutical Statistics, 2009, 19, 414-423.	0.8	4
87	Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T).. Journal of Clinical Oncology, 2017, 35, 192-192.	1.6	4
88	A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer.. Journal of Clinical Oncology, 2017, 35, 80-80.	1.6	4
89	Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 2022, 40, 300-307.	2.6	4
90	Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial.. Journal of Clinical Oncology, 2022, 40, 5012-5012.	1.6	4

#	ARTICLE	IF	CITATIONS
91	Quantitative endoscopy in the chemoprevention of Barrett's Esophagus Trial. Ecological Management and Restoration, 2008, 21, 641-644.	0.4	3
92	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer, 2019, 19, 572.	2.6	3
93	A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer. Advances in Radiation Oncology, 2021, 6, 100679.	1.2	3
94	Symptom Outcomes of Cancer Patients With Clival Metastases Treated With Radiotherapy: A Study of 44 Patients. Anticancer Research, 2021, 41, 5001-5006.	1.1	3
95	Development and pilot test of a physician-focused cancer clinical trials communication training intervention. PEC Innovation, 2022, 1, 100012.	0.8	3
96	Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types. Journal of Molecular Diagnostics, 2021, 23, 1761-1773.	2.8	2
97	Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2022, 40, 287-287.	1.6	2
98	Comprehensive genomic profiling of penile squamous cell carcinoma and impact of HPV status on immune-checkpoint inhibition-related biomarkers.. Journal of Clinical Oncology, 2022, 40, 4-4.	1.6	2
99	Updated biomarker results from a phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE).. Journal of Clinical Oncology, 2022, 40, 119-119.	1.6	2
100	A pancancer analysis of impact of <i>MDM2/MDM4</i> on immune checkpoint blockade (ICB).. Journal of Clinical Oncology, 2022, 40, 2630-2630.	1.6	2
101	New Targets in the Management of Prostate Cancer. Hematology/Oncology Clinics of North America, 2006, 20, 985-999.	2.2	1
102	Malignant undifferentiated sex cord-stromal testis tumor with brain metastasis: Case report. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 53-55.	1.6	1
103	Reply to G. Procopio et al. Journal of Clinical Oncology, 2014, 32, 3083-3084.	1.6	1
104	Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.. Journal of Clinical Oncology, 2021, 39, 5063-5063.	1.6	1
105	Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA).. Journal of Clinical Oncology, 2021, 39, 5058-5058.	1.6	1
106	Neutrophil lymphocyte ratio (NLR) as a clinical biomarker predictive of outcomes with immune checkpoint inhibitor therapy in genitourinary cancers.. Journal of Clinical Oncology, 2017, 35, 453-453.	1.6	1
107	Immune evaluation study of sipuleucel-T (Sip-T) in African-American and European-American men with castration-resistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, 206-206.	1.6	1
108	A phase II study of muscadine grape skin extract in men with biochemically recurrent prostate cancer.. Journal of Clinical Oncology, 2017, 35, 248-248.	1.6	1

#	ARTICLE	IF	CITATIONS
109	Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men. <i>Prostate</i> , 2022, , .	2.3	1
110	PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS191-TPS191.	1.6	1
111	Phase 2 randomized trial of ModraDoc006/r, oral docetaxel plus ritonavir, versus intravenous docetaxel in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 117-117.	1.6	1
112	Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4545-4545.	1.6	1
113	Molecular correlates of Delta-like-ligand 3 (DLL3) expression in neuroendocrine neoplasms (NENs).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4127-4127.	1.6	1
114	Preface. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 375-376.	5.9	0
115	Prostate Cancer National Summitâ€™s Call to Action. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 161-168.	1.9	0
116	Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 415-415.	1.6	0
117	Reassessment of a proposed molecular classification system for clear cell renal cell cancer (ccRCC): Results from a randomized phase II trial of pazopanib.. <i>Journal of Clinical Oncology</i> , 2012, 30, 404-404.	1.6	0
118	Neutrophil lymphocyte ratio (NLR) as a predictor of outcomes with immune checkpoint inhibitor (ICI) therapy in genitourinary cancer and melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 37-37.	1.6	0
119	Development of a patient question prompt list to improve communication and clinical trial enrollment in a diverse patient population.. <i>Journal of Clinical Oncology</i> , 2017, 35, 143-143.	1.6	0
120	Interlesional response assessment with ¹⁸ F-sodium fluoride (¹⁸ F-NaF) PET/CT in men with chemotherapy-naïve bone metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5036-5036.	1.6	0
121	Targeted Therapy Trials for Prostate Cancer. , 2008, , 383-400.		0
122	Molecular and immune landscape of <i>FH</i> -mutated kidney cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 382-382.	1.6	0
123	Genomic and immunologic profiles of concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4571-4571.	1.6	0
124	PACCT: An intervention to improve communication quality and clinical trial invitations for Black and White men with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24137-e24137.	1.6	0
125	A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5016-5016.	1.6	0
126	Landscape analysis of urothelial carcinoma (UC) by telomerase reverse transcriptase (<i>TERT</i>) alterations.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4524-4524.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Characterization and impact of canonical Wnt Signaling Pathway (WSP) alterations on outcomes of metastatic prostate cancer.. Journal of Clinical Oncology, 2022, 40, 5053-5053.	1.6	0
128	Incorporation of inpatient response heterogeneity using ¹⁸ F-NaF PET/CT imaging improves outcome prediction models for metastatic prostate cancer patients.. Journal of Clinical Oncology, 2022, 40, e13554-e13554.	1.6	0
129	Molecular and immune landscape of <i>FH</i> -mutated cancers.. Journal of Clinical Oncology, 2022, 40, 3125-3125.	1.6	0